Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 13/20 | 0.61 |
| ▸ | AURKA | O14965 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5477225 | 0.97 | EPHB4 (0.62) | EPHB4AURKAMAPTKDM4EALDH1A1 | |
| SCHEMBL5477605 | 0.93 | EPHB4 (0.58) | EPHB4AURKAMAPTCNR1 | |
| SCHEMBL5490521 | 0.92 | EPHB4 (0.58) | EPHB4AURKAMAPTKDM4EALDH1A1 | |
| SCHEMBL5481263 | 0.92 | EPHB4 (0.53) | EPHB4AURKAMAPTKDM4EALDH1A1 | |
| SCHEMBL5475066 | 0.91 | EPHB4 (0.61) | EPHB4AURKAMAPTCNR1 | |
| SCHEMBL5485343 | 0.91 | EPHB4 (0.55) | EPHB4AURKAMAPTKDM4EALDH1A1 | |
| SCHEMBL5481752 | 0.90 | EPHB4 (0.60) | EPHB4AURKAMAPTCNR1 | |
| SCHEMBL5482286 | 0.90 | EPHB4 (0.57) | EPHB4AURKA | |
| SCHEMBL6514368 | 0.89 | EPHB4 (0.62) | EPHB4AURKAMAPTKDM4EALDH1A1 | |
| SCHEMBL5482279 | 0.87 | EPHB4 (0.55) | EPHB4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078136-A1 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | claimed |
| US-7160885-B2 | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity | CGI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | claimed |
| US-20050054649-A1 | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-A]pyrazines as modulators of Hsp90 complex activity | XEROX CORPORATION | 2005-03-10 | — | — | US | claimed |
| US-7160885-B2 | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity | CGI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160885-B2 | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity | CGI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160885-B2 | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity | CGI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050054649-A1 | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-A]pyrazines as modulators of Hsp90 complex activity | XEROX CORPORATION | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078136-A1 | Fused heterocyclic compounds useful as kinase modulators | MAP3K2, MAP3K3, MAP4K2 | EPHB4 3142/4885AURKA 314/4885MAPT 3377/4885 |
| US-20050054649-A1 | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-A]pyrazines as modulators of Hsp90 complex activity | HSP90AB1, HSP90AA1, HSPA9 | EPHB4 4724/4885AURKA 2642/4885MAPT 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.